Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide in Pediatric Participants, Ages 6 to 17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) and of Linaclotide Versus Placebo in Pediatric Participants With Functional Constipation (FC)

    Summary
    EudraCT number
    2019-001500-38
    Trial protocol
    NL   BE   GB   HU   EE   DE   PL   BG   IT  
    Global end of trial date
    29 May 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    16 Nov 2024
    First version publication date
    16 Nov 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    LIN-MD-64
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04026113
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    AbbVie Deutschland GmbH & Co. KG
    Sponsor organisation address
    AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6 4UB
    Public contact
    Global Medical Services, AbbVie, 001 8006339110, abbvieclinicaltrials@abbvie.com
    Scientific contact
    Global Medical Services, AbbVie, 001 8006339110, abbvieclinicaltrials@abbvie.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    EMEA-000927-PIP01-10
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    29 May 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    29 May 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (72 μg daily) in comparison with placebo in pediatric participants, 6 to 17 years of age, who fulfill modified Rome III Criteria for Child/Adolescent FC. The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (145 μg or 290 μg daily) in pediatric participants, 7 to 17 years of age, who fulfill the Rome III criteria for child/adolescent IBS and modified Rome III criteria for child/adolescent FC.
    Protection of trial subjects
    Subject and/or legal guardian read and understood the information provided about the study and gave written permission.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Oct 2019
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Canada: 5
    Country: Number of subjects enrolled
    Estonia: 1
    Country: Number of subjects enrolled
    Israel: 4
    Country: Number of subjects enrolled
    Italy: 1
    Country: Number of subjects enrolled
    Netherlands: 6
    Country: Number of subjects enrolled
    Ukraine: 5
    Country: Number of subjects enrolled
    United States: 416
    Worldwide total number of subjects
    438
    EEA total number of subjects
    8
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    226
    Adolescents (12-17 years)
    212
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 64 sites, in 7 countries. Participants were randomized in a 1:1 ratio for 12 weeks during the double-blind (DB) study intervention period: • FC participants received either linaclotide 72 μg or placebo • IBS-C participants received either linaclotide 145 μg or 290 μg

    Pre-assignment
    Screening details
    Participants were considered to have completed the study after the DB and Post-Intervention periods. However, the Post-Intervention period was not required for those who enrolled into an open-label, long-term safety study after completing the DB period.

    Period 1
    Period 1 title
    Double-Blind Treatment Period (12 Weeks)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Carer, Assessor
    Blinding implementation details
    A list of participant randomization codes were generated by statistical programming and implemented by the interactive Web response system vendor (an electronic version will be stored on a secure server). This list will identify each participant by randomization number and include the participant’s corresponding intervention assignment.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    FC Participants: Placebo
    Arm description
    Placebo single dose, once daily at approximately the same time each day, 30 minutes before any meal.
    Arm type
    Experimental

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)

    Arm title
    FC Participants: Linaclotide 72 μg
    Arm description
    Linaclotide 72 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.
    Arm type
    Placebo

    Investigational medicinal product name
    Linaclotide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)

    Arm title
    IBS-C Participants: Linaclotide 145 μg
    Arm description
    Linaclotide 145 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.
    Arm type
    Experimental

    Investigational medicinal product name
    Linaclotide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)

    Arm title
    IBS-C Participants: Linaclotide 290 μg
    Arm description
    Linaclotide 290 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.
    Arm type
    Experimental

    Investigational medicinal product name
    Linaclotide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)

    Number of subjects in period 1
    FC Participants: Placebo FC Participants: Linaclotide 72 μg IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg
    Started
    164
    166
    55
    53
    Randomized and Treated
    164
    164
    55
    53
    Completed
    145
    148
    52
    46
    Not completed
    19
    18
    3
    7
         Consent withdrawn by subject
    7
    5
    1
    5
         Physician decision
    1
    1
    1
    -
         Other, not specified
    4
    3
    -
    1
         Adverse event
    2
    2
    -
    -
         Noncompliance with study drug
    -
    4
    -
    -
         Lost to follow-up
    4
    -
    1
    -
         Lack of efficacy
    1
    2
    -
    1
         Protocol deviation
    -
    1
    -
    -
    Period 2
    Period 2 title
    Post-Intervention Period (1 Week)
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    FC Participants: Placebo
    Arm description
    Placebo single dose, once daily at approximately the same time each day, 30 minutes before any meal.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    FC Participants: Linaclotide 72 μg
    Arm description
    Linaclotide 72 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    IBS-C Participants: Linaclotide 145 μg
    Arm description
    Linaclotide 145 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    IBS-C Participants: Linaclotide 290 μg
    Arm description
    Linaclotide 290 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 2 [1]
    FC Participants: Placebo FC Participants: Linaclotide 72 μg IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg
    Started
    66
    75
    20
    20
    Completed
    65
    75
    19
    20
    Not completed
    1
    0
    1
    0
         Other, not specified
    1
    -
    1
    -
    Notes
    [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
    Justification: The Post-Intervention period was not required for those who enrolled into an open-label, long-term safety study after completing the DB period.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    FC Participants: Placebo
    Reporting group description
    Placebo single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    FC Participants: Linaclotide 72 μg
    Reporting group description
    Linaclotide 72 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    IBS-C Participants: Linaclotide 145 μg
    Reporting group description
    Linaclotide 145 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    IBS-C Participants: Linaclotide 290 μg
    Reporting group description
    Linaclotide 290 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group values
    FC Participants: Placebo FC Participants: Linaclotide 72 μg IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg Total
    Number of subjects
    164 166 55 53 438
    Age categorical
    Units: Subjects
        6-11 years
    91 92 22 21 226
        12-17 years
    73 74 33 32 212
    Gender categorical
    Units: Subjects
        Female
    86 96 31 34 247
        Male
    78 70 24 19 191
    Race
    Units: Subjects
        White
    114 116 40 35 305
        Black or African American
    45 42 13 14 114
        Asian
    2 3 2 1 8
        American Indian or Alaska Native
    1 0 0 0 1
        Native Hawaiian or other Pacific Islander
    1 3 0 0 4
        Multiple
    1 2 0 1 4
        Missing
    0 0 0 2 2
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    77 72 19 17 185
        Not Hispanic or Latino
    87 94 36 36 253

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    FC Participants: Placebo
    Reporting group description
    Placebo single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    FC Participants: Linaclotide 72 μg
    Reporting group description
    Linaclotide 72 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    IBS-C Participants: Linaclotide 145 μg
    Reporting group description
    Linaclotide 145 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    IBS-C Participants: Linaclotide 290 μg
    Reporting group description
    Linaclotide 290 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.
    Reporting group title
    FC Participants: Placebo
    Reporting group description
    Placebo single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    FC Participants: Linaclotide 72 μg
    Reporting group description
    Linaclotide 72 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    IBS-C Participants: Linaclotide 145 μg
    Reporting group description
    Linaclotide 145 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    IBS-C Participants: Linaclotide 290 μg
    Reporting group description
    Linaclotide 290 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Primary: Functional Constipation (FC) Participants: Change From Baseline in 12-week SBM (Spontaneous Bowel Movement) Frequency Rate (SBMs/Week) During the Study Intervention Period

    Close Top of page
    End point title
    Functional Constipation (FC) Participants: Change From Baseline in 12-week SBM (Spontaneous Bowel Movement) Frequency Rate (SBMs/Week) During the Study Intervention Period [1]
    End point description
    An SBM is defined as a BM that occurs in the absence of laxative, enema, or suppository use on the calendar day of the bowel movement (BM) or the calendar day before the BM. Assessments of BM characteristics that determine occurrences of SBM (ie, BM frequency and rescue medication use) were measured by using the eDiary completed twice daily (morning and evening) on the eDiary (Electronic Diary) device. Modified intent to treat (mITT) Population: randomized participants who received ≥1 dose of double-blind (DB) study drug. Participants with analysis values at both baseline and postbaseline during the specified time period.
    End point type
    Primary
    End point timeframe
    Baseline, 12 Weeks
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: IBS-c and FC participant endpoints and analyses are presented separately per protocol.
    End point values
    FC Participants: Placebo FC Participants: Linaclotide 72 μg
    Number of subjects analysed
    164
    164
    Units: SBMs
        least squares mean (standard error)
    1.050 ( 0.187 )
    2.220 ( 0.187 )
    Statistical analysis title
    Statistical Analysis 1
    Comparison groups
    FC Participants: Placebo v FC Participants: Linaclotide 72 μg
    Number of subjects included in analysis
    328
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001 [2]
    Method
    ANCOVA
    Parameter type
    Difference
    Point estimate
    1.17
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.651
         upper limit
    1.689
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.264
    Notes
    [2] - ANCOVA model estimates/t-tests comparing specified treatment groups, controlling for age group and baseline value.
    Statistical analysis title
    Statistical Analysis 2
    Comparison groups
    FC Participants: Placebo v FC Participants: Linaclotide 72 μg
    Number of subjects included in analysis
    328
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.4323 [3]
    Method
    ANCOVA
    Confidence interval
    Notes
    [3] - Treatment-by-Age Group Interaction P-value: Interaction P-value base on ANCOVA model with treatment, age group, treatment-by-age group interaction as factors and baseline value as a covariate.

    Primary: Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks APS (Abdominal Pain and SBM) + 2 Responder Rate

    Close Top of page
    End point title
    Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks APS (Abdominal Pain and SBM) + 2 Responder Rate [4] [5]
    End point description
    6/12 weeks APS + 2 responder=participant who meets the weekly APS + 2 responder criteria ≥6 of the 12 weeks of the intervention period. Weekly APS +2 responder=participant who has an increase of ≥2 in the SBM weekly rate from baseline, AND a decrease of ≥30% in mean abdominal pain score from baseline, during that study intervention week. Assessments of abdominal pain and BM characteristics that determine occurrences of SBMs were measured by using an eDiary completed twice daily (AM and PM). Assessments of abdominal pain were measured using a 5-point scale where 0=none and 4=a lot. A participant's abdominal pain score=mean of the non-missing abdominal pain scores during the specified period. Responder rate=percentage of participants who were 6/12 weeks APS + 2 responders. A participant had to have ≥4 completed diary days in the analysis week to be considered a responder for that week and was otherwise considered a non-responder for that week. mITT Population
    End point type
    Primary
    End point timeframe
    12 Weeks
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Planned statistical analyses are presented in data table.
    [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: IBS-c and FC participant endpoints and analyses are presented separately per protocol.
    End point values
    IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg
    Number of subjects analysed
    53
    47
    Units: percentage of participants
        number (not applicable)
    22.6
    23.4
    No statistical analyses for this end point

    Secondary: Functional Constipation (FC) Participants: Change From Baseline in 12-week Stool Consistency During the Study Intervention Period

    Close Top of page
    End point title
    Functional Constipation (FC) Participants: Change From Baseline in 12-week Stool Consistency During the Study Intervention Period [6]
    End point description
    Stool consistency was measured twice daily, once in the morning and once in the evening eDiary, using the 7-point ordinal pediatric Bristol Stool Form Scale (p-BSFS): Type 1: Looks like small hard lumps or balls, like pebbles; Type 2: Looks like fat sausage shape but lumpy and hard; Type 3: Looks like a sausage but with cracks on it; Type 4: Looks like a sausage or snake, smooth and soft; Type 5: Looks like chicken nuggets, soft smooth blobs; Type 6: Looks like oatmeal, fluffy mushy pieces; Type 7: Looks like a milkshake, watery. A participant's p-BSFS score for the study intervention period was the average of the non-missing p-BSFS scores from the SBMs reported by the participant during the 12-week study intervention period. Modified Intent-to-Treat (mITT) Population: all randomized participants who received at least 1 dose of double-blind study intervention. Participants with analysis values at both baseline and postbaseline during the specified time period.
    End point type
    Secondary
    End point timeframe
    Baseline, up to 12 weeks
    Notes
    [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: IBS-c and FC participant endpoints and analyses are presented separately per protocol.
    End point values
    FC Participants: Placebo FC Participants: Linaclotide 72 μg
    Number of subjects analysed
    132
    135
    Units: units on a scale
        least squares mean (standard error)
    0.685 ( 0.078 )
    1.108 ( 0.077 )
    Statistical analysis title
    Statistical Analysis 1
    Comparison groups
    FC Participants: Linaclotide 72 μg v FC Participants: Placebo
    Number of subjects included in analysis
    267
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0001 [7]
    Method
    ANCOVA
    Parameter type
    Difference
    Point estimate
    0.423
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.208
         upper limit
    0.638
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.109
    Notes
    [7] - ANCOVA model estimates/t-tests comparing specified treatment groups, controlling for age group and baseline value.
    Statistical analysis title
    Statistical Analysis 2
    Comparison groups
    FC Participants: Placebo v FC Participants: Linaclotide 72 μg
    Number of subjects included in analysis
    267
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.4381 [8]
    Method
    ANCOVA
    Confidence interval
    Notes
    [8] - Treatment-by-Age Group Interaction P-value: Interaction P-value base on ANCOVA model with treatment, age group, treatment-by-age group interaction as factors and baseline value as a covariate.

    Secondary: Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week SBM Frequency Rate (SBMs/Week) During the Study Intervention Period

    Close Top of page
    End point title
    Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week SBM Frequency Rate (SBMs/Week) During the Study Intervention Period [9]
    End point description
    An SBM is defined as a BM that occurs in the absence of laxative, enema, or suppository use on the calendar day of the BM or the calendar day before the BM. Assessments of BM characteristics that determine occurrences of SBM (ie, BM frequency and rescue medication use) were measured by using the eDiary completed twice daily (morning and evening) on the eDiary (Electronic Diary) device. A participant's SBMs/week for the study intervention period was the average of the non-missing SBMs/week reported by the participant during the 12-week study intervention period. mITT Population: randomized participants who received ≥1 dose of DB study drug. Participants with analysis values at both baseline and postbaseline during the specified time period.
    End point type
    Secondary
    End point timeframe
    Baseline, up to 12 Weeks
    Notes
    [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: IBS-c and FC participant endpoints and analyses are presented separately per protocol.
    End point values
    IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg
    Number of subjects analysed
    53
    47
    Units: SBMs/week
        arithmetic mean (standard deviation)
    2.347 ( 3.3335 )
    2.747 ( 2.8861 )
    No statistical analyses for this end point

    Secondary: Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week Abdominal Pain During the Study Intervention Period

    Close Top of page
    End point title
    Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week Abdominal Pain During the Study Intervention Period [10]
    End point description
    Assessments of abdominal pain were measured twice daily, once in the morning and once in the evening eDiary, using a 5-point scale where a score of 0 indicates no abdominal pain scores and a score of 4 indicates a lot of abdominal pain. Assessments of abdominal pain were measured using a 5-point scale where '0' indicates no abdominal pain and '4' indicates a lot of abdominal pain. The participant's abdominal pain score was derived as the mean of the non-missing morning and evening abdominal pain scores during the specified period. mITT Population: randomized participants who received ≥1 dose of DB study drug. Participants with analysis values at both baseline and postbaseline during the specified time period.
    End point type
    Secondary
    End point timeframe
    Baseline, up to 12 Weeks
    Notes
    [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: IBS-c and FC participant endpoints and analyses are presented separately per protocol.
    End point values
    IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg
    Number of subjects analysed
    53
    47
    Units: units on a scale
        arithmetic mean (standard deviation)
    -0.837 ( 0.9313 )
    -0.837 ( 0.8809 )
    No statistical analyses for this end point

    Secondary: Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week Stool Consistency During the Study Intervention Period

    Close Top of page
    End point title
    Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week Stool Consistency During the Study Intervention Period [11]
    End point description
    Stool consistency was measured twice daily, once in the morning and once in the evening eDiary, using the 7-point ordinal p-BSFS (pediatric Bristol Stool Form Scale: Type 1: Looks like small hard lumps or balls, like pebbles Type 2: Looks like fat sausage shape but lumpy and hard Type 3: Looks like a sausage but with cracks on it Type 4: Looks like a sausage or snake, smooth and soft Type 5: Looks like chicken nuggets, soft smooth blobs Type 6: Looks like oatmeal, fluffy mushy pieces Type 7: Looks like a milkshake, watery. A participant's p-BSFS score for the study intervention period was the average of the non-missing p-BSFS scores from the SBMs reported by the participant during the 12-week study intervention period. mITT Population: randomized participants who received ≥1 dose of DB study drug. Participants with analysis values at both baseline and postbaseline during the specified time period.
    End point type
    Secondary
    End point timeframe
    Baseline, up to 12 weeks
    Notes
    [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: IBS-c and FC participant endpoints and analyses are presented separately per protocol.
    End point values
    IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg
    Number of subjects analysed
    47
    39
    Units: units on a scale
        arithmetic mean (standard deviation)
    0.979 ( 1.2900 )
    1.358 ( 1.1288 )
    No statistical analyses for this end point

    Secondary: Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks SBM + 2 Responder Rate

    Close Top of page
    End point title
    Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks SBM + 2 Responder Rate [12]
    End point description
    A 6/12 weeks SBM + 2 responder is a participant that meets the weekly SBM + 2 responder criteria for at least 6 out of the 12 weeks of the intervention period. A weekly SBM +2 responder is a participant who has an increase of at least 2 in the SBM weekly rate from baseline, Assessments of BM characteristics that determine occurrences of SBMs (ie, BM frequency and rescue medication use) were measured by using an eDiary completed twice daily (morning and evening). Responder rate is presented as the percentage of participants who were 6/12 weeks SBM + 2 responders. mITT Population: randomized participants who received ≥1 dose of DB study drug. Participants with analysis values at both baseline and postbaseline during the specified time period.
    End point type
    Secondary
    End point timeframe
    12 Weeks
    Notes
    [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: IBS-c and FC participant endpoints and analyses are presented separately per protocol.
    End point values
    IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg
    Number of subjects analysed
    53
    47
    Units: percentage of participants
        number (not applicable)
    30.2
    29.8
    No statistical analyses for this end point

    Secondary: Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks Abdominal Pain Responder

    Close Top of page
    End point title
    Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks Abdominal Pain Responder [13]
    End point description
    A 6/12 weeks abdominal pain responder is a participant that meets the weekly abdominal pain responder criteria for at least 6 out of the 12 weeks of the intervention period. A weekly abdominal pain responder is a participant who has a decrease of at least 30% in the mean abdominal pain score from baseline, during that study intervention week. Assessments of abdominal pain were measured by using an eDiary completed twice daily (morning and evening) and were measured using a 5-point scale where '0' indicates no abdominal pain and '4' indicates a lot of abdominal pain. The participant's abdominal pain score was derived as the mean of the non-missing abdominal pain scores during the specified period. Responder rate is presented as the percentage of participants who were 6/12 weeks abdominal pain responders. mITT Population: randomized participants who received ≥1 dose of DB study drug. Participants with analysis values at both baseline and postbaseline during the specified time period.
    End point type
    Secondary
    End point timeframe
    12 Weeks
    Notes
    [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: IBS-c and FC participant endpoints and analyses are presented separately per protocol.
    End point values
    IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg
    Number of subjects analysed
    53
    47
    Units: percentage of participants
        number (not applicable)
    49.1
    42.6
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Up to 13 weeks
    Adverse event reporting additional description
    All randomized participants
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    25.0
    Reporting groups
    Reporting group title
    IBS-C Participants: Linaclotide 145 μg
    Reporting group description
    Linaclotide 145 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    IBS-C Participants: Linaclotide 290 μg
    Reporting group description
    Linaclotide 290 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    FC Participants: Placebo
    Reporting group description
    Placebo single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Reporting group title
    FC Participants: Linaclotide 72 μg
    Reporting group description
    Linaclotide 72 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.

    Serious adverse events
    IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg FC Participants: Placebo FC Participants: Linaclotide 72 μg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 53 (0.00%)
    2 / 164 (1.22%)
    2 / 166 (1.20%)
         number of deaths (all causes)
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    Gastrointestinal disorders
    DIARRHOEA
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 53 (0.00%)
    0 / 164 (0.00%)
    1 / 166 (0.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FAECALOMA
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 53 (0.00%)
    0 / 164 (0.00%)
    1 / 166 (0.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    SUICIDE ATTEMPT
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 53 (0.00%)
    2 / 164 (1.22%)
    0 / 166 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SUICIDAL IDEATION
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 53 (0.00%)
    1 / 164 (0.61%)
    0 / 166 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 2%
    Non-serious adverse events
    IBS-C Participants: Linaclotide 145 μg IBS-C Participants: Linaclotide 290 μg FC Participants: Placebo FC Participants: Linaclotide 72 μg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    7 / 55 (12.73%)
    4 / 53 (7.55%)
    10 / 164 (6.10%)
    11 / 166 (6.63%)
    Gastrointestinal disorders
    ABDOMINAL PAIN
         subjects affected / exposed
    2 / 55 (3.64%)
    0 / 53 (0.00%)
    2 / 164 (1.22%)
    1 / 166 (0.60%)
         occurrences all number
    2
    0
    2
    1
    DIARRHOEA
         subjects affected / exposed
    4 / 55 (7.27%)
    4 / 53 (7.55%)
    3 / 164 (1.83%)
    6 / 166 (3.61%)
         occurrences all number
    4
    4
    3
    6
    CONSTIPATION
         subjects affected / exposed
    2 / 55 (3.64%)
    0 / 53 (0.00%)
    0 / 164 (0.00%)
    1 / 166 (0.60%)
         occurrences all number
    2
    0
    0
    1
    Infections and infestations
    COVID-19
         subjects affected / exposed
    2 / 55 (3.64%)
    1 / 53 (1.89%)
    5 / 164 (3.05%)
    4 / 166 (2.41%)
         occurrences all number
    2
    1
    5
    4

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    05 Jun 2020
    The purpose of Global Protocol Amendment 1 was to include enrollment of pediatric participants ages 7 – 17 years with IBS-C, to include a plan for a potential interim analysis to assess futility for FC participants, and to provide additional clarification and updates to the LIN-MD-64 protocol (dated 17 April 2019).

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 02:24:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA